EA201892137A1 - Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию - Google Patents

Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию

Info

Publication number
EA201892137A1
EA201892137A1 EA201892137A EA201892137A EA201892137A1 EA 201892137 A1 EA201892137 A1 EA 201892137A1 EA 201892137 A EA201892137 A EA 201892137A EA 201892137 A EA201892137 A EA 201892137A EA 201892137 A1 EA201892137 A1 EA 201892137A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions
locuses
application
enhanced expression
Prior art date
Application number
EA201892137A
Other languages
English (en)
Inventor
Роберт Бабб
Дарья Бураков
Ганг Чен
Джеймс П. Фандл
Original Assignee
Регенерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Регенерон Фармасьютикалз, Инк. filed Critical Регенерон Фармасьютикалз, Инк.
Publication of EA201892137A1 publication Critical patent/EA201892137A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к сайт-специфической интеграции и экспрессии рекомбинантных белков в эукариотических клетках. В частности, настоящее изобретение предусматривает композиции и способы для обеспечения улучшенной экспрессии антител, в том числе биспецифических антител, в эукариотических клетках, в частности в линиях клеток китайского хомячка (Cricetulus griseus), посредством применения локуса, обеспечивающего повышенную экспрессию.
EA201892137A 2016-04-20 2017-04-20 Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию EA201892137A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325385P 2016-04-20 2016-04-20
PCT/US2017/028552 WO2017184831A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of an expression-enhancing locus

Publications (1)

Publication Number Publication Date
EA201892137A1 true EA201892137A1 (ru) 2019-03-29

Family

ID=58701850

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892137A EA201892137A1 (ru) 2016-04-20 2017-04-20 Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию

Country Status (15)

Country Link
US (2) US11530277B2 (ru)
EP (1) EP3445780A1 (ru)
JP (2) JP7134868B2 (ru)
KR (2) KR20180134894A (ru)
CN (2) CN116004544A (ru)
AR (1) AR108295A1 (ru)
AU (2) AU2017253240B2 (ru)
BR (1) BR112018071285A2 (ru)
CA (1) CA3015371A1 (ru)
EA (1) EA201892137A1 (ru)
IL (2) IL262268B2 (ru)
MX (1) MX2018012866A (ru)
SG (2) SG10202010156XA (ru)
TW (1) TW201803981A (ru)
WO (1) WO2017184831A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018392728A1 (en) * 2017-12-22 2020-07-09 Genentech, Inc. Targeted integration of nucleic acids
WO2020034097A1 (en) * 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
SG11202103334YA (en) * 2018-10-26 2021-05-28 Hoffmann La Roche Multispecific antibody screening method using recombinase mediated cassette exchange
KR20210107057A (ko) * 2018-12-21 2021-08-31 제넨테크, 인크. 핵산의 표적화 통합
MX2021011837A (es) * 2019-03-29 2021-10-22 Hoffmann La Roche Método para la generación de una célula que expresa el receptor neonatal de región de fragmento cristalizable (fcrn) mediante la integración dirigida de múltiples casetes de expresión en una organización definida.
CA3134705A1 (en) 2019-04-02 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Method of introducing target-specific foreign gene
CN114008081A (zh) * 2019-06-19 2022-02-01 豪夫迈·罗氏有限公司 通过以限定的组织形式靶向整合多个表达盒来产生二价双特异性抗体表达细胞的方法
WO2020254357A1 (en) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Method for the generation of a protein expressing cell by targeted integration using cre mrna
CA3140323A1 (en) 2019-06-19 2020-12-24 Johannes Auer Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
CN114258403A (zh) * 2019-06-19 2022-03-29 豪夫迈·罗氏有限公司 通过以限定的组织形式靶向整合多个表达盒来产生多价多特异性抗体表达细胞的方法
BR112021025401A2 (pt) * 2019-06-19 2022-02-01 Hoffmann La Roche Métodos para produzir um anticorpo trivalente, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante, composição e método para produzir uma célula de mamífero recombinante
KR20240117146A (ko) * 2021-12-22 2024-07-31 제넨테크, 인크. 다중 벡터 재조합효소 매개 카세트 교환

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
DK1531666T3 (da) 2002-05-29 2014-01-13 Regeneron Pharma Inducerbart eukaryot-ekspressionssystem
US20050019925A1 (en) 2002-11-14 2005-01-27 Genentech, Inc. Intron fusion construct and method of using for selecting high-expressing production cell lines
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
EP2115136A4 (en) 2006-12-21 2010-05-19 Glaxosmithkline Llc NOVEL PROCEDURE
WO2008089396A1 (en) 2007-01-19 2008-07-24 Invitrogen Corporation Compositions and methods for genetic manipulation and monitoring of cell lines
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
WO2008151219A1 (en) * 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
HUE038596T2 (hu) 2009-06-02 2018-10-29 Regeneron Pharma Fukoziláció-hiányos sejtek
EP3916011A1 (en) 2009-06-26 2021-12-01 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
MX338953B (es) 2010-08-16 2016-05-06 Novimmune Sa Metodos para la generacion de anticuerpos multiespecificos y multivalentes.
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI675044B (zh) 2012-11-14 2019-10-21 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX2017005306A (es) 2014-10-23 2018-01-09 Regeneron Pharma Novedosos sitios de integracion en celulas cho y usos de estos.
ES2901133T3 (es) 2015-09-23 2022-03-21 Regeneron Pharma Anticuerpos biespecíficos anti-CD3 optimizados y usos de los mismos

Also Published As

Publication number Publication date
JP2019514358A (ja) 2019-06-06
SG11201807881VA (en) 2018-10-30
WO2017184831A1 (en) 2017-10-26
AU2017253240A1 (en) 2018-09-20
EP3445780A1 (en) 2019-02-27
CA3015371A1 (en) 2017-10-26
KR20210135340A (ko) 2021-11-12
SG10202010156XA (en) 2020-11-27
JP2022164824A (ja) 2022-10-27
JP7546015B2 (ja) 2024-09-05
CN116004544A (zh) 2023-04-25
JP7134868B2 (ja) 2022-09-12
CN109071633B (zh) 2022-11-18
AR108295A1 (es) 2018-08-08
MX2018012866A (es) 2019-03-11
CN109071633A (zh) 2018-12-21
BR112018071285A2 (pt) 2019-02-12
US20230322956A1 (en) 2023-10-12
TW201803981A (zh) 2018-02-01
IL262268B1 (en) 2024-01-01
IL262268A (en) 2018-11-29
US20190263937A1 (en) 2019-08-29
AU2017253240B2 (en) 2024-07-04
US11530277B2 (en) 2022-12-20
IL309065A (en) 2024-02-01
IL262268B2 (en) 2024-05-01
KR102474757B1 (ko) 2022-12-07
KR20180134894A (ko) 2018-12-19
AU2024220126A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
EA201892137A1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EA201892010A1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EA201992001A1 (ru) Композиции и способы повышения экспрессии генов
EA201991168A1 (ru) Белок, связывающий простатический специфический мембранный антиген
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
EA201791918A1 (ru) Модификация белков клеток-хозяев
ZA202208710B (en) Anti-vegf protein compositions and methods for producing the same
MX2017000083A (es) Compuestos de platino, composiciones y usos de estos.
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
EA201892588A1 (ru) Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации
EA201501028A1 (ru) Конструкции митохондриальных белков и их применение
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение
EA201990758A1 (ru) Способ получения электрокомпетентных дрожжевых клеток и способ применения указанных клеток
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
CR20210088A (es) Composiciones de anticuerpos fcrn y métodos de uso de estos
EA201790241A1 (ru) Эффективная селективность в отношении рекомбинантных белков
EA201900275A1 (ru) Стероиды и их конъюгаты с белками
AR103810A1 (es) Modificación de proteína de célula hospedante
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение